Clinical trials: Thalidomide
Head and Neck Cancer
Thalidomide in Treating Patients With Thyroid Cancer
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
- Trial name
- NCT00026533
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Kenneth Ain
MALT Lymphoma
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.
- Trial name
- NCT00373646
- Testing
- Thalidomide, Pharmion
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Kidney, Cancer
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment.
- Trial name
- NCT00277017
- Testing
- 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Metastatic Colorectal Cancer
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
Thalidomide has both anti-angiogenesis and antiemetic effects, and its combined use with TAS-102 may reduce the gastrointestinal reactions associated with TAS-102, while enhancing antitumor efficacy and reducing the side effects…
- Trial name
- NCT05266820
- Testing
- Thalidomide, TAS-102
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Transfusion Dependent Beta Thalassemia
Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia
Beta thalassemia Major (BTM) is the most common hemoglobinopathy caused by mutations in the beta-globin gene . Worldwide, approximately 80 million people carry thalassemia gene mutation.
- Trial name
- Thal-H (NCT07292259)
- Testing
- ADDITION OF THALIDOMIDE AND HYDROXYUREA
- Where
- 9 sites in Pakistan
- Volunteers
- 100 people
- Sponsor
- Pakistan Blood and Marrow Transplant (PBMT) Group
Multiple Myeloma
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma cells, depriving them of key support signals…
- Trial name
- NCT01537861
- Testing
- Filgrastim, Bortezomib, Carfilzomib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Ovarian Cancer
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of ovarian cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004876
- Testing
- carboplatin, thalidomide
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Amyotrophic Lateral Sclerosis, ALS
Phase II Study Using Thalidomide for the Treatment of ALS
The use of Thalidomide in patients with ALS who have disease progression.
- Trial name
- NCT00140452
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Myeloma
VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates
Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope for the patients with multiple myeloma.
- Trial name
- NCT00320476
- Testing
- Velcade
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Korean Multiple Myeloma Working Party
Multiple Myeloma
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed…
- Trial name
- T-BiRD (NCT00538733)
- Testing
- thalomid, lenalidomide, clarithromycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Response, Acute Phase, Survivorship
Two Schemes Response in Multiple Myeloma
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
- Trial name
- NCT06284395
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 83 people
- Sponsor
- Hospital General de Mexico
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Randomized phase II trial to determine the effectiveness of monoclonal antibody therapy in…
- Trial name
- NCT00019539
- Testing
- bevacizumab, thalidomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Crohn Disease
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
Crohn's disease (CD) is a life-long inflammatory bowel disease disease with an unknown pathogenesis. The ultimate goal of therapy is to modify the natural history of CD thus reducing complications.
- Trial name
- NCT03221166
- Testing
- Thalidomide, Infliximab
- Where
- 6 sites in Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS Burlo Garofolo
Chronic Lymphocytic Leukaemia
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy (response rate) of oral lenalidomide in the treatment of patients with symptomatic, previously untreated, chronic lymphocytic leukemia (CLL), toxicity of lenalidomide in patients with CLL as…
- Trial name
- Rev-CLL (NCT00751296)
- Testing
- Lenalidomide
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University Health Network, Toronto
Solid Tumor Cancer
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
- Trial name
- GEMINI (NCT07671534)
- Testing
- Gemcitabine, Mitomycin C, Thalidomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and…
- Trial name
- NCT06279351
- Testing
- Thalidomide+cetuximab+FOLFOX/FOLFIRI
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Xinqiao Hospital of Chongqing
Unspecified Childhood Solid Tumor, Protocol Specific
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003754
- Testing
- cyclophosphamide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multicentric Castleman Disease
TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
To explore the effectiveness and safety of thalidomide, cyclophosphamide and prednisone (TCP regimen) in newly diagnosed Multicentric Castleman's disease (MCD) patients.
- Trial name
- NCT03043105
- Testing
- Thalidomide, cyclophosphamide and prednisone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
T-LGL Leukemia, Clpd-Nk
TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia.
- Trial name
- NCT04453345
- Testing
- thalidomide + prednisone + methotrexate
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of…
- Trial name
- NCT03896737
- Testing
- Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
- Where
- 24 sites in Czechia, Greece and 1 more
- Volunteers
- 401 people
- Sponsor
- European Myeloma Network B.V.